Form 4 Filing: Hari Parameswaran Acquires (Grant) shares of Obsidian Therapeutics, Inc.

STOCK AWARD / GRANT

⚡ MATERIALITY: 1/10

corporate issuer

Obsidian Therapeutics, Inc.

Ticker: not matched

Transaction Value

N/A (Non-Open-Market)

Price/Share: $0.00 (Non-Open-Market)

transaction date

2026-08-03

Shares: 331,173

HillSignal AI Analytical Report

SEC Form 4 documents direct changes in beneficial ownership of securities for public corporations. The reporting insider, Hari Parameswaran, holds the title of Chief Medical Officer at Obsidian Therapeutics, Inc..

On 2026-08-03, the insider transacted 331,173 shares.This transaction is a non-open-market event (such as a stock grant or option exercise) with a reported price per share of $0.00.

Executive Summary Summary

Hari Parameswaran (Chief Medical Officer) was granted $0 of $OBX

Post-Transaction Position: 331,173 shares

SEC Accession No: 0001193125-26-460933 (CIK: 2145750)

Verified Multi-Source Index

Verify the accuracy of this insider transaction and corporate entity independently. HillSignal pulls data directly from official SEC databases; use the sources below to corroborate.

SEC EDGAR FilingView Source Form 4

OpenCorporates RegistryVerify Corporate Identity

Google NewsObsidian Therapeutics, Inc. News Coverage